[go: up one dir, main page]

MX2022001820A - Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). - Google Patents

Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).

Info

Publication number
MX2022001820A
MX2022001820A MX2022001820A MX2022001820A MX2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A
Authority
MX
Mexico
Prior art keywords
compound
hydroxyoctadeca
sphingosine
enyl
phosphoric
Prior art date
Application number
MX2022001820A
Other languages
English (en)
Inventor
Stephan D Parent
Melanie Janelle Bevill
Hideomi Kijima
Takayuki Fujito
Courtney S Johnson
Shuhei Otani
Naoko Imura
Travis Lee Houston
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2022001820A publication Critical patent/MX2022001820A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un objeto de la presente invención es proporcionar un compuesto con un equilibrio mejorado de la actividad agonista para los receptores S1P5 en relación con los receptores, y una forma adecuada para las sustancias farmacológicas de los productos farmacéuticos. Se proporciona el Compuesto I que tiene una alta actividad agonista selectiva del receptor S1P5 sobre el receptor S1P1. Además, las formas cristalinas del Compuesto I, las sales del Compuesto I, y las formas cristalinas de las sales del mismo descritas en la presente invención se proporcionan como sustancias farmacológicas de productos farmacéuticos.
MX2022001820A 2019-08-20 2020-08-19 Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). MX2022001820A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889091P 2019-08-20 2019-08-20
PCT/JP2020/031326 WO2021033729A1 (ja) 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形

Publications (1)

Publication Number Publication Date
MX2022001820A true MX2022001820A (es) 2022-03-17

Family

ID=74660224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001820A MX2022001820A (es) 2019-08-20 2020-08-19 Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).

Country Status (16)

Country Link
US (1) US12459890B2 (es)
EP (1) EP4019496B1 (es)
JP (1) JP7409383B2 (es)
KR (1) KR20220050886A (es)
CN (1) CN114302873A (es)
AU (1) AU2020334489B2 (es)
BR (1) BR112022002632A2 (es)
CA (1) CA3150303A1 (es)
ES (1) ES2983098T3 (es)
IL (1) IL290432A (es)
MX (1) MX2022001820A (es)
MY (1) MY207001A (es)
PH (1) PH12022550319A1 (es)
TW (1) TWI859303B (es)
WO (1) WO2021033729A1 (es)
ZA (1) ZA202201784B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757869B (zh) * 2018-02-22 2024-03-08 小野药品工业株式会社 具有s1p5受体激动活性的化合物
WO2022266162A1 (en) 2021-06-16 2022-12-22 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
EP4633736A1 (en) * 2022-12-16 2025-10-22 Celgene Corporation Heterocyclic compounds as modulators of s1p5
WO2025119254A1 (en) * 2023-12-06 2025-06-12 Ono Pharmaceutical Co., Ltd. Method for preparing dihydronaphthalene derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222495A (en) * 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
GB8725118D0 (en) * 1987-10-27 1987-12-02 Ciba Geigy Ag Rifamycin derivatives
JP2005020882A (ja) 2003-06-25 2005-01-20 Matsushita Electric Works Ltd モータアクチュエータ装置
US7825109B2 (en) 2003-08-29 2010-11-02 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
KR101186386B1 (ko) 2003-08-29 2012-09-26 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
JP2006064757A (ja) 2004-08-24 2006-03-09 Systec Kyowa:Kk ディスプレイ固定用スタンド
EP2371811B1 (en) * 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
CA2641718A1 (en) 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
EA017984B1 (ru) 2006-06-12 2013-04-30 Новартис Аг Кристаллические безводные формы лактата n-гидрокси-3-[4-[[[2-(2-метил-1h-индол-3-ил)этил]амино]метил]фенил]-2e-2-акриламида
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
ES2602173T3 (es) 2011-02-07 2017-02-17 Biogen Ma Inc. Agentes moduladores S1P
WO2016088834A1 (ja) * 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
EP3409658B9 (en) 2016-01-29 2024-07-17 ONO Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative
CN111757869B (zh) 2018-02-22 2024-03-08 小野药品工业株式会社 具有s1p5受体激动活性的化合物
JP7354960B2 (ja) * 2019-08-20 2023-10-03 小野薬品工業株式会社 Ｓ１ｐ５介在性疾患の予防および／または治療剤

Also Published As

Publication number Publication date
IL290432A (en) 2022-04-01
ES2983098T3 (es) 2024-10-22
EP4019496B1 (en) 2024-06-05
NZ785003A (en) 2024-09-27
TW202114984A (zh) 2021-04-16
CA3150303A1 (en) 2021-02-25
US12459890B2 (en) 2025-11-04
AU2020334489B2 (en) 2025-10-30
EP4019496A1 (en) 2022-06-29
TWI859303B (zh) 2024-10-21
ZA202201784B (en) 2024-02-28
PH12022550319A1 (en) 2022-12-19
JP7409383B2 (ja) 2024-01-09
JPWO2021033729A1 (es) 2021-02-25
BR112022002632A2 (pt) 2022-05-03
MY207001A (en) 2025-01-23
KR20220050886A (ko) 2022-04-25
EP4019496A4 (en) 2023-01-11
AU2020334489A1 (en) 2022-03-03
WO2021033729A1 (ja) 2021-02-25
US20220289675A1 (en) 2022-09-15
CN114302873A (zh) 2022-04-08

Similar Documents

Publication Publication Date Title
MX2022001820A (es) Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).
CR20130500A (es) Moduladores de los receptores de hormonas nucleares
UY33317A (es) Nuevos derivados de pirazol
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CU20130094A7 (es) Moduladores de la vía del complemento
BR112015032330A2 (pt) Carboxamidas primárias como inibidores de bkt
DOP2009000237A (es) Derivados de indazol oxadiazol sustituidos para uso como agonistas esfingosina 1-fosfato (s1p)
CR20160007A (es) Nuevos compuestos triciclicos
MX2013014978A (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
ECSP109979A (es) Preparación sólida que contiene alogliptina y clorhidrato de metformina
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR090126A1 (es) Composicion de doxilamina y piridoxina y/o sus metabolitos o sales
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
DOP2013000305A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX2019009224A (es) Diacilhidrazina cristalina y sus usos.
UY35223A (es) Moduladores heterocíclicos de receptores de hormonas nucleares
CR20130158A (es) Derivados de 1,4-oxazepina
MX390507B (es) Compuestos de amida y su uso.
AR065519A1 (es) Sales de adicion de acido, hidratos y polimorfos de la etil - amida del acido 5- (2,4- dihidroxi -5- isopropil - fenil )-4-(4- morfolin-4-il-metil - fenil ) - isoxasol-3- carboxilico y formulaciones que comprenden estas formas
BR112013012715A2 (pt) "ácidos fosfônicos como moduladores de receptores de s1p".
MX2023011920A (es) Compuestos de 1,3,4-oxadiazol tiocarbonilo como inhibidores de histona deacetilasa 6, y composicion farmaceutica que los comprende.
EA201301150A1 (ru) Новые пиперидинилмонокарбоновые кислоты в качестве агонистов s1p1 рецепторов
UY34647A (es) Composiciones farmacéuticas
MX2022010794A (es) Sales y formas cristalinas de un agonista del receptor 1 asociado a aminas traza (taar1).